NewCardio, Inc., through its wholly-owned subsidiary, NewCardio Technologies, Inc., focuses on the research, development, and commercialization of software and hardware products and services for the non-invasive diagnosis and monitoring of cardiovascular disease worldwide. It also involves in the cardiac safety assessment of various drugs that are under development. The company develops a technology platform that provides real-time, 3-D analysis of the heart's electrical activity as detected at the body surface by 12-lead electrocardiogram electrodes. NewCardio, Inc. has three products under various stages of development: QTinno, an automated software tool suite that provides QT interval data from a range of electrocardiograms; VisualECG, a set of algorithms and tools that provide a method to describe cardiac electrical activity in time and space; and CardioBip, a mobile electrocardiogram transtelephonic system comprising a mobile electrocardiogram recording and transmitting device, and a diagnostic center that receives, processes, and analyzes the data. The company is based in Santa Clara, California.